X

XORTX Therapeutics
D

XRTX

1.22000
USD
0.01
(0.83%)
Market Closed
Volume
500
EPS
-2
Div Yield
-
P/E
10
Market Cap
3,932,749
OverviewSignalsIdeasNews
Related Instruments
    ABT
    ABT
    0.850
    (0.74%)
    118.14 USD
    BDX
    BDX
    -2.040
    (-0.90%)
    225.190 USD
    H
    HOLX
    1.040
    (1.34%)
    78.600 USD
    IDXX
    IDXX
    -2.54
    (-0.60%)
    421.30 USD
    ISRG
    ISRG
    -10.30
    (-1.92%)
    536.48 USD
    R
    RGEN
    -17.400
    (-12.22%)
    124.960 USD
    RMD
    RMD
    3.500
    (1.51%)
    234.840 USD
    T
    TECH
    -4.920
    (-6.79%)
    67.590 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    514.06 USD
    More
News

Title: XORTX Therapeutics

Sector: Healthcare
Industry: Biotechnology
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.